Synairgen Share Discussion Threads

[nobbygnome] 23/5/2020 14:06

Great points as always timbo!

[timbo003] 23/5/2020 13:53

>>>>rossannan

Yes, early treatment with SNG001 may lead to improved outcomes compared to later treatment, but I think one of the main objectives when Synairgen were planning the COVID clinical program was to obtain a rapid and unambiguous answer to whether SNG001 could be effective in treating COVID patients. To this end, a hospital based study was always likely to give a quicker and cleaner result than an outpatient study.

Back in January/February when they first started planning the program there was already a similar hospital based study ongoing (in COPD) and RM did state in one of his interviews, that large parts of the COVID protocol were a copy and paste job from the COPD protocol.

In addition it is probably fair to say that in general it is easier to keep tight control of a hospital based study compared to an outpatient study . There is likely to be better compliance with the protocol, smaller numbers of patients, faster completion and greater study power.

[nobbygnome] 23/5/2020 13:31

It is worth reiterating that the paper highlighted last weekend from China showed that in hospitalised patients, inhaled alpha interferon had beneficial effects on viral load and IL-6 levels. That is a strong hint that the hospital trial will be positive IMHO.

[coxypete] 23/5/2020 13:29

That is a partial driver behind home trials - to see if the drug in a home setting could be administered to help people earlier on.

[nobbygnome] 23/5/2020 13:27

I am not sure we need to go into a blame game which is the current way of the world apparently. A short sharp trial of easily recruited hospital patients is the low hanging fruit which can give a quick result. A home study is much more difficult to set up and will take longer. There is a reasonable rational for both but I don't dispute probably better for the home study. I am more than happy that they have taken the route they chose; it seems to me some investors want the impossible of a result to everything now! They took the best route to get a quick result in the current feverish, Armageddon like environment!

A positive result in the hospital study would be massive but not the end of the road because of all the other possibilities ongoing.

[slinkyj] 23/5/2020 13:08

This share has been target priced on results, find me facts Sparta about SNG that would make me take my money out before the results. We all know the risks of trials in biotech so that doesn't count as we would be out of here by now. Nothing to add then there's a rectangular thing called a door.

[myst1] 23/5/2020 13:01

Based on all the research to date, I am confident that SNG001 will be a winner, but is it not generally the case that a patient that has been admitted to hospital would have had the virus for more than say 72 hrs?

Is there a concern that the hospital trial results may not be as encouraging due to the timing only of the trial and not the drugs real potential?

[spartan attack] 23/5/2020 12:52

Nobby hasn't a clue and should be filtered immediately

[nobbygnome] 23/5/2020 11:52

>> D1NGA

That would take a major protocol change and aint going to happen. Anyway for me the potential commercial opportunity in the short term if the hospital trial is positive, is too good to miss.

[d1nga] 23/5/2020 11:45

Rafboy

That's why I was hoping that the trial data would be held until the home trial data was gathered, as I think that's where we need to be hitting the virus, before hospitalisation takes place.

[nobbygnome] 23/5/2020 11:41

That is a very good point. With most drugs the earlier you treat the better but probably even more of a truism with SNG001 because of the mode of action.

[rafboy] 23/5/2020 11:32

Seems to me as a layman, that the earlier interferon beta is given via a nebuliser, the better it is for the patient. That’s why I think the home trials are so important. If SNG could become the initial treatment on suspected Covid19 that would be very beneficial for all concerned.

[nobbygnome] 23/5/2020 09:23

Patients on a ventilator are excluded from the trial so all patients will be before that stage at least at the start of the trial.

[toffeeman] 23/5/2020 09:21

Injected Interferon and glucocorticoids are problematic as Faron know only too well:

This is a crucial publication for the critical care community, detailing the important scientific detective work that has been undertaken since the unexpected readout from the INTEREST trial. It is especially important in these times when ICUs are filled with COVID-19 patients, many of whom may be receiving treatment with glucocorticoids. Prior clinical data have shown that glucocorticoids are harmful in viral-induced ARDS and the World Health Organization has already recommended not to use glucocorticoids in severely ill COVID-19 patients. These published and peer-reviewed data give us the mechanistic reason why and the results are without dispute. The potential lung protective effects of interferon beta through upregulation of CD73, should it be endogenous or exogenous, are lost with the administration of glucocorticoids

[waterloo01] 23/5/2020 09:07

I'd add my penny's worth re that the report a few posts above, which is a retrospective review, that suggests that survival was only marginally improved in patients already on ventilation and that earlier use should be explored.

As far as I'm aware, and Nobby might well correct me, SNG will be given to patients pre ventilation. Can't see how you could get an inhailed drug into a ventilated patient.

[nobbygnome] 23/5/2020 08:58

The problem with the injected interferon beta is that you have to give a high dose to get enough to the lungs. It has a short half-life as do all cytokines because they are dangerous molecules when present in high concentrations so evolution has ensured they disappear quickly. The PEGylated version may well be better because you can give a lower dose although there may well still be systemic effects because it stays around for longer.

Now PEG is something I know an awful lot about....

[nobbygnome] 23/5/2020 08:53

>> bob

Zero chance of the results being on Tuesday....

[lauders] 23/5/2020 03:53

Let's hope that the inhaled version of interferon B is more promising that the feedback on this injected study:

I still think we should be higher than we are now in a week or two or three, but of course we will no doubt have some choppy waters to negotiate between now and the results. I can predict it will not be dull!

PS. The last sentence of the above is where we are "at", and with the inhaled format.

Further assessment of the earlier administration of this drug in randomized trials is recommended.

On the other hand interferon is talked about positively here:

Stat says that the discovery could lead to interferon-based therapies meant to counteract the effect of the virus on interferon genes. A third study also published in preprint form by researchers at the University of Texas Medical Branch shows that interferon IFN-1 can block the coronavirus from replicating as efficiently in lab conditions. Vineet Menachery and his team proved the virus has “a difficult time replicating” if IFN-1 is added to the dish. After a few days, the interferon-treated cells had a viral load 1,000 to 10,000 times lower than the cells where the virus was able to replicate at will.

Menachery says that type-1 interferon “could stop the virus before it could get established.” Interferon would let the cells know that a pathogen is there and allow them to limit the spread of COVID-19. Interferon is already used to treat various illnesses, including hepatitis and cancer, but it does come with side effects.

Clinical trials will be needed to establish a course of action, Stat says. But what the report doesn’t mention is a different study, which I alluded to before, which proved that adding interferon to two other antivirals could speed up recovery times. Doctors in Hong Kong combined interferon beta-1b, lopinavir-ritonavir (Kaletra), and ribavirin in COVID-19 therapies and found that the patients recovered in an average of seven days. The patients who were only given Kaletra needed 12 days to recover.

Separately, Stanford University has been recruiting volunteers to test a therapy based on a different type of interferon, peginterferon lambda-1a.

[bobaxe1] 23/5/2020 01:16

I have a theory, mms maybe know the results are out tues and nobody knows the results so they hedged their bets buy giving us a low close just incase lol

[cl81227] 22/5/2020 22:13

Thanks Nobby
Just unfiltered now

[spartan attack] 22/5/2020 20:56

Ah its nobby

Funny , you said that when i made first comment 55p

haha

[nobbygnome] 22/5/2020 20:52

Please all filter Spartan Attack. He is a troll of the very worst kind and nothing useful will come of any discourse with him.

[l0ngterm] 22/5/2020 20:52

I expect a drop, hopefully indicating the Final sell off from the IIs, as they reach their target. I also think some PIs and others are waiting for that.